Safety Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops

  • days left to enroll
  • participants needed
  • sponsor
    Sylentis, S.A.
Updated on 4 April 2021


Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.

Condition Choroidal Neovascularization, Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers, Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers
Treatment SYL18001 sodium Low dose q.d, SYL18001 sodium Middle dose q.d, SYL18001 sodium High dose q.d, SYL18001 sodium High dose b.i.d
Clinical Study IdentifierNCT04782271
SponsorSylentis, S.A.
Last Modified on4 April 2021


Yes No Not Sure

Inclusion Criteria

Signed informed consent
Body mass index (BMI) between 19.5 and 29.0 kg/m2
Intraocular pressure (IOP) <=21 mmHg
Best Corrected Visual Acuity (BCVA) >= 70 ETDRS
Normal corneal and conjunctival assessment
Normal funduscopy

Exclusion Criteria

Pregnant or breastfeeding females or those with a positive pregnancy test. Females of childbearing potential who will not use a medically acceptable contraceptive method
Current relevant diseases according to the investigator's judgement
Previous relevant chronic processes according to the investigator's judgement
Relevant visual alterations according to the investigator's judgement
Administration of systemic medications
Case history of hypersensitivity to medicinal products or any other allergic process
Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note